Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Lab-on-a-Chip & Microfluidics Europe 2019

Daniel Irimia's Biography



Daniel Irimia, Associate Professor, Surgery Department, Massachusetts General Hospital (MGH), Shriners Burns Hospital, and Harvard Medical School

Daniel Irimia is a bioengineer, a medical doctor by training, and a researcher in the areas of microfluidics, inflammation, and sepsis. He is an Associate Professor in the Surgery Department at Massachusetts General Hospital (MGH), Shriners Burns Hospital, and Harvard Medical School. He is a leader in the design of novel tools for measuring human neutrophil activities in health and disease. He was recently awarded the "Pioneers of Miniaturization" prize from the Chemical and Biological Microsystems Society for his work on microfluidic tools for analyzing neutrophils and other leukocytes.

Daniel Irimia Image

Microfluidic Assay for the Diagnosis of Sepsis from a Drop of Blood

Wednesday, 19 June 2019 at 08:00

Add to Calendar ▼2019-06-19 08:00:002019-06-19 09:00:00Europe/LondonMicrofluidic Assay for the Diagnosis of Sepsis from a Drop of BloodLab-on-a-Chip and Microfluidics Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Sepsis is a deadly condition which ends the life of more than 5 million people worldwide every year, more than heart disease and stroke combined.  Sepsis is often misdiagnosed, delaying treatment.  To improve the survival of sepsis patients, new capabilities for diagnosis and monitoring of sepsis are needed.  Towards this goal, we focused on neutrophils, the most numerous white blood cells and earliest responders to infections and sepsis.  Recently, we uncovered a unique neutrophil phenotype during sepsis.  The phenotype can only be measured while neutrophils are still in blood and vanishes after neutrophils are isolated from blood. Newly designed microfluidic assays that use blood directly were instrumental for this discovery.  So far, we validated the new neutrophil phenotype as an accurate biomarker for sepsis in three cohorts of patients in intensive care.  Further studies will enhance our understanding of the roles that neutrophils play before and during sepsis and will facilitate the design of new strategies for the diagnosis, monitoring, and prevention of sepsis.


Add to Calendar ▼2019-06-18 00:00:002019-06-19 00:00:00Europe/LondonLab-on-a-Chip and Microfluidics Europe 2019Lab-on-a-Chip and Microfluidics Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com